Navigation Links
Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
Date:2/24/2011

preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma, or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure, and death.  For full prescribing information, visit www.acetadote.net.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

Important Note Regarding Forward-Looking and External Statements

This press release contains forward-looking statements that reflect Cumberland's current views with respect to future events, based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of opera
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
2. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
3. Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
4. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
5. Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
6. Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010
7. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
8. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
11. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Today FRC Action joined 19 pro-life groups in a letter sent to Food ... consideration for FDA approval that can cause abortions but is misleadingly labeled as an "emergency ... Tom McClusky ... the following comments: , , , ...
... INDIANAPOLIS , July 28 Eli Lilly and Company (NYSE: ... the Federal Circuit has upheld a prior ruling by the U.S. District Court ... invalid. , , , ... ruling by the U.S. Court of Appeals regarding Gemzar,s method-of-use patent. We continue ...
Cached Medicine Technology:FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
(Date:7/10/2014)... 2014 Up to 70% of Parkinson,s disease ... their quality of life. Some patients have disturbed ... staying asleep, while other patients may be subject ... the extreme, PD patients may exhibit REM-sleep behavior ... dream re-enactment, even before motor symptoms appear. A ...
(Date:7/10/2014)... of Huddersfield could help to improve the quality of ... such as butter, mayonnaise, yoghurt and fruit drinks ... for her work. , Katerina gained her MSc degree ... now she has embarked on research for a PhD. ... is investigating the potential of carbohydrates extracted from the ...
(Date:7/10/2014)... 2014) A research review identifying the clinical indicators ... step in the process of developing evidence-based guidelines for ... report published by Neurosurgery , official ... . The journal is published by Lippincott Williams ... Kluwer Health . , Based on analysis of ...
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2
... five-year international clinical study shows that acyclovir, a commonly prescribed ... not affect HIV transmission by people with both viruses. ... Transmission Study, was released by the New England Journal ... will follow in the print edition Feb. 4. ...
... ... Second Wave of H1N1 Flu: No Waiting in Long Lines , ... San Diego, Calif. (Vocus) January 25, 2009 -- U.S. ... nation, announced today that they are offering H1N1 vaccine shots for $15 per shot for ...
... for surgery than county hospitals, research shows , MONDAY, ... received by prostate cancer patients is influenced by the ... a new U.S. study has found. , Surgery was ... while patients in private facilities were more likely to ...
... , ROCHESTER, Minn. , Jan. ... the brain is the aim of a new Mayo Clinic project ... The new method uses analytics technology developed by the Mayo and ... 95 percent accuracy rate in detecting aneurysms, compared with 70 percent ...
... , NEW YORK , ... of the 25 largest PR firms ( http://www.5wpr.net/ ) in the U.S., today ... its versatile roster of fashion and lifestyle clients. Launched in 2002, the luxury ... lifestyle products using proprietary natural frequency technology. , " Philip Stein is ...
... CHESAPEAKE, Va. , Jan. 25 U.S.-based, Maison ... Haiti -based Maison Fortune Orphanage. The strategic expansion plans ... after the recent devastating earthquakes. The Orphanage, located near the ... in a sea of unimaginable turmoil. , This planned expansion ...
Cached Medicine News:Health News:Control of herpes symptoms does not reduce HIV transmission, international study found 2Health News:U.S. HealthWorks in San Diego Region Offering $15 H1N1 Vaccinations for both Walk-Ins and On-Site 2Health News:Prostate Cancer Care Varies By Hospital Type 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 3Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 4Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 2Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 3Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 2Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 3
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: